(Q37089330)

18 August 2017

Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase (English)

1 reference

18 August 2017

1 reference

1 reference

1

Marsden CD

1 reference

18 August 2017

Barry PE

2

1 reference

18 August 2017

Parkes JD

series ordinal

3

1 reference

18 August 2017

Zilkha KJ

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 1973

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

18 August 2017

1 reference

18 August 2017

36

1 reference

18 August 2017

1

1 reference

18 August 2017

10-14

1 reference

Treatment of Parkinson's disease with levodopa and Ro 4-4602

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Modification of Parkinsonism--chronic treatment with L-dopa

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Treatment of Parkinson's disease with amantadine and levodopa. A one-year study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=494269

Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)

27 June 2018

1 reference

12 December 2020

[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

1 reference

12 December 2020

Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor

1 reference

12 December 2020

1 reference

12 December 2020

Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.36.1.10

1 reference

18 August 2017

1 reference

18 August 2017

1 reference